¹⁸F- FDG PET Reveals a Nucleus Accumbens-Centered Metabolic Network Correlating With Clinical Severity in Anti-LGI1 Encephalitis

Abstract

The metabolic signature of anti-leucine-rich glioma-inactivated 1 (anti-LGI1) autoimmune encephalitis remains poorly defined. We sought to delineate disease-specific ¹⁸F-FDG PET patterns and assess their relationships with clinical severity and cognition. Forty-seven patients with anti-LGI1 encephalitis and 25 healthy controls underwent ¹⁸F-FDG PET/CT, and voxel-wise comprised to identify regional metabolic alterations. A disease-specific metabolic pattern was derived with fivefold cross-validation, and a metabolic covariance network was mapped using the Brainnetome atlas. Pattern expression scores were correlated with clinical assessments. Compared to controls, patients demonstrated hypermetabolism in the hippocampal rostal, nucleus accumbens (NAc), and hypothalamus, alongside hypometabolism in the dorsolateral prefrontal cortex and posterior cingulate cortex (PCC). We identified a robust metabolic pattern centered on the NAc with extensions to the hippocampus, prefrontal cortex, and PCC; expression of this pattern correlated positively with both clinical severity and cognitive impairment. Subgroup analyses showed no significant differences in basal ganglia metabolism between patients with and without faciobrachial dystonic seizures (FBDS), or in hypothalamic metabolism between those with and without hyponatremia. Overall, ¹⁸F-FDG PET uncovers a NAc-centered metabolic network that parallels disease severity in anti-LGI1 encephalitis. Our study offers potential biomarker for clinical evaluation and provides valuable insights into the underlying pathogenesis of clinical manifestations.

Keywords

anti-LGI1 encephalitis / degree of disease severity / metabolic covariation / PET

References

[1] B. de Freitas Dias, F. Fieni Toso, M. E. Slhessarenko Fraife Barreto, et al., “Brazilian Autoimmune Encephalitis Network (BrAIN): Antibody Profile and Clinical Characteristics From a Multicenter Study,” Frontiers in Immunology 14 (2023): 1256480.

[2] A. Rodriguez, C. J. Klein, E. Sechi, et al., “LGI1 Antibody Encephalitis: Acute Treatment Comparisons and Outcome,” Journal of Neurology, Neurosurgery, and Psychiatry 93, no. 3 (2022): 309–315.

[3] A. E. M. Bastiaansen, R. W. van Steenhoven, M. de Bruijn, et al., “Autoimmune Encephalitis Resembling Dementia Syndromes,” Neurology Neuroimmunology and NeuroInflammation 8, no. 5 (2021): e1039.

[4] E. P. Flanagan, M. D. Geschwind, A. S. Lopez-Chiriboga, et al., “Autoimmune Encephalitis Misdiagnosis in Adults,” JAMA Neurology 80, no. 1 (2023): 30–39.

[5] H. Ford, S. Griffith, N. Warren, et al., “Psychiatric Manifestations of Autoimmune Encephalitis,” Autoimmunity Reviews 21, no. 9 (2022): 103145.

[6] M. J. Kelly, E. Grant, A. G. Murchison, et al., “Magnetic Resonance Imaging Characteristics of LGI1-Antibody and CASPR2-Antibody Encephalitis,” JAMA Neurology 81, no. 5 (2024): 525–533.

[7] R. W. Van Steenhoven, J. M. de Vries, A. L. Bruijstens, et al., “Mimics of Autoimmune Encephalitis: Validation of the 2016 Clinical Autoimmune Encephalitis Criteria,” Neurology Neuroimmunology and NeuroInflammation 10, no. 6 (2023): e200148.

[8] A. Gadoth, S. J. Pittock, D. Dubey, et al., “Expanded Phenotypes and Outcomes Among 256 LGI1/CASPR2-IgG-Positive Patients,” Annals of Neurology 82, no. 1 (2017): 79–92.

[9] M. Liang, N. Niu, C. Jia, et al., “Diagnostic Superiority of 18 F-FDG PET Over MRI in Detecting Anti-LGI1 Autoimmune Encephalitis: A Comparative Study With Insights Into Faciobrachial Dystonic Seizures Mechanisms and Recurrence Identification,” Clinical Nuclear Medicine 48, no. 11 (2023): e516–e522.

[10] E. Rissanen, K. Carter, S. Cicero, et al., “Cortical and Subcortical Dysmetabolism Are Dynamic Markers of Clinical Disability and Course in Anti-LGI1 Encephalitis,” Neurology Neuroimmunology and NeuroInflammation 9, no. 2 (2022): e1136.

[11] M. S. Sadaghiani, S. Roman, L. A. Diaz-Arias, et al., “Comparison of Quantitative FDG-PET and MRI in Anti-LGI1 Autoimmune Encephalitis,” Neuroradiology 65, no. 8 (2023): 1225–1238.

[12] L. Liu, Z. Lyu, H. Li, L. Bai, Y. Wan, and P. Li, “Enhancing the Clinical Diagnosis of the Acute and Subacute Phases of Autoimmune Encephalitis and Predicting the Risk Factors: The Potential Advantages of 18F-FDG PET/CT,” BMC Medical Imaging 23, no. 1 (2023): 193.

[13] S. Park, H. Choi, G. J. Cheon, K. Wook Kang, and D. S. Lee, “18F-FDG PET/CT in Anti-LGI1 Encephalitis: Initial and Follow-Up Findings,” Clinical Nuclear Medicine 40, no. 2 (2015): 156–158.

[14] N. Seniaray, R. Verma, R. Ranjan, E. Belho, and H. Mahajan, “Metabolic Imaging Patterns on 18F-FDG PET in Acute and Subacute LGI1 Autoimmune Limbic Encephalitis,” Clinical Nuclear Medicine 46, no. 1 (2021): e27–e28.

[15] A. Gadoth, M. Nisnboym, Y. Alcalay, et al., “Electrolyte Imbalance in Anti-LGI1 Encephalitis: It Is Not All in Your Head,” Neurology Neuroimmunology and NeuroInflammation 10, no. 6 (2023): e200155.

[16] B. J. Burkett, D. R. Johnson, C. H. Hunt, S. A. Messina, and S. M. Broski, “Anti-LGI1 Autoimmune Epilepsy,” Clinical Nuclear Medicine 48, no. 11 (2023): 956–957.

[17] T. Kaaden, M. Madlener, K. Angstwurm, et al., “Seizure Semiology in Antibody-Associated Autoimmune Encephalitis,” Neurology Neuroimmunology and NeuroInflammation 9, no. 6 (2022): e200034.

[18] Q. Li, Y. Zhao, Y. Hu, et al., “Linked Patterns of Symptoms and Cognitive Covariation With Functional Brain Controllability in Major Depressive Disorder,” EBioMedicine 106 (2024): 105255.

[19] J. Wang, J. Ge, and L. Jin, “Characterization of Neuroinflammation Pattern in Anti-LGI1 Encephalitis Based on TSPO PET and Symptom Clustering Analysis,” European Journal of Nuclear Medicine and Molecular Imaging 50, no. 8 (2023): 2394–2408.

[20] J. H. Yoon, M. J. Minzenberg, S. Ursu, et al., “Association of Dorsolateral Prefrontal Cortex Dysfunction With Disrupted Coordinated Brain Activity in Schizophrenia: Relationship With Impaired Cognition, Behavioral Disorganization, and Global Function,” American Journal of Psychiatry 165, no. 8 (2008): 1006–1014.

[21] T. Shao, J. Huang, Y. Zhao, et al., “Metformin Improves Cognitive Impairment in Patients With Schizophrenia: Associated With Enhanced Functional Connectivity of Dorsolateral Prefrontal Cortex,” Translational Psychiatry 13, no. 1 (2023): 315.

[22] L. K. White, W. Makhoul, M. Teferi, Y. I. Sheline, and N. L. Balderston, “The Role of dlPFC Laterality in the Expression and Regulation of Anxiety,” Neuropharmacology 224 (2023): 109355.

[23] S. Rezakhani, M. Amiri, A. Hassani, K. Esmaeilpour, and V. Sheibani, “Anodal HD-tDCS on the Dominant Anterior Temporal Lobe and Dorsolateral Prefrontal Cortex: Clinical Results in Patients With Mild Cognitive Impairment,” Alzheimer's Research & Therapy 16, no. 1 (2024): 27.

[24] Y. Xiong, C. Ye, Y. Chen, et al., “Altered Functional Connectivity of Basal Ganglia in Mild Cognitive Impairment and Alzheimer's Disease,” Brain Sciences 12, no. 11 (2022): 1555.

[25] M. D'Esposito and B. R. Postle, “The Cognitive Neuroscience of Working Memory,” Annual Review of Psychology 66 (2015): 115–142.

[26] G. S. Kirshenbaum, C. Y. Chang, M. Bompolaki, et al., “Adult-Born Neurons Maintain Hippocampal Cholinergic Inputs and Support Working Memory During Aging,” Molecular Psychiatry 28, no. 12 (2023): 5337–5349.

[27] J. Giorgio, J. N. Adams, A. Maass, W. J. Jagust, and M. Breakspear, “Amyloid Induced Hyperexcitability in Default Mode Network Drives Medial Temporal Hyperactivity and Early Tau Accumulation,” Neuron 112, no. 4 (2024): 676–686.e4.

[28] I. M. McDonough, S. B. Festini, and M. M. Wood, “Risk for Alzheimer's Disease: A Review of Long-Term Episodic Memory Encoding and Retrieval fMRI Studies,” Ageing Research Reviews 62 (2020): 101133.

[29] N. B. Kroemer, N. Opel, V. Teckentrup, et al., “Functional Connectivity of the Nucleus Accumbens and Changes in Appetite in Patients with Depression,” JAMA Psychiatry 79, no. 10 (2022): 993–1003.

[30] C. Loane, G. P. D. Argyropoulos, A. Roca-Fernandez, et al., “Hippocampal Network Abnormalities Explain Amnesia After VGKCC-Ab Related Autoimmune Limbic Encephalitis,” Journal of Neurology, Neurosurgery, and Psychiatry 90, no. 9 (2019): 965–974.

[31] M. R. Gilmartin, N. L. Balderston, and F. J. Helmstetter, “Prefrontal Cortical Regulation of Fear Learning,” Trends in Neuroscience (Tins) 37, no. 8 (2014): 455–464.

[32] L. F. Barrett and W. K. Simmons, “Interoceptive Predictions in the Brain,” Nature Reviews Neuroscience 16, no. 7 (2015): 419–429.

[33] A. N. Goldstein-Piekarski, T. M. Ball, Z. Samara, et al., “Mapping Neural Circuit Biotypes to Symptoms and Behavioral Dimensions of Depression and Anxiety,” Biological Psychiatry 91, no. 6 (2022): 561–571.

[34] Z. Sha, T. D. Wager, A. Mechelli, and Y. He, “Common Dysfunction of Large-Scale Neurocognitive Networks Across Psychiatric Disorders,” Biological Psychiatry 85, no. 5 (2019): 379–388.

[35] L. M. Williams, “Precision Psychiatry: A Neural Circuit Taxonomy for Depression and Anxiety,” Lancet Psychiatry 3, no. 5 (2016): 472–480.

[36] B. Holt-Gosselin, A. S. Keller, M. Chesnut, R. Ling, K. A. Grisanzio, and L. M. Williams, “Greater Baseline Connectivity of the Salience and Negative Affect Circuits Are Associated With Natural Improvements in Anxiety Over Time in Untreated Participants,” Journal of Affective Disorders 295 (2021): 366–376.

[37] P. C. Tu, W. C. Chang, T. P. Su, et al., “Thalamocortical Functional Connectivity and Rapid Antidepressant and Antisuicidal Effects of Low-Dose Ketamine Infusion Among Patients With Treatment-Resistant Depression,” Molecular Psychiatry 30, no. 1 (2025): 61–68.

[38] T. Yang, D. W. Bayless, Y. Wei, et al., “Hypothalamic Neurons That Mirror Aggression,” Cell 186, no. 6 (2023): 1195–1211.e19.

[39] A. Datta, C. Saha, P. Godse, M. Sharma, D. Sarmah, and P. Bhattacharya, “Neuroendocrine Regulation in Stroke,” Trends in Endocrinology and Metabolism 34, no. 5 (2023): 260–277.

[40] A. Tsui, M. Richards, A. Singh-Manoux, C. Udeh-Momoh, and D. Davis, “Longitudinal Associations Between Diurnal Cortisol Variation and Later-Life Cognitive Impairment,” Neurology 94, no. 2 (2020): e133–e141.

[41] Y. D. Li, Y. J. Luo, Z. K. Chen, et al., “Hypothalamic Modulation of Adult Hippocampal Neurogenesis in Mice Confers Activity-Dependent Regulation of Memory and Anxiety-Like Behavior,” Nature Neuroscience 25, no. 5 (2022): 630–645.

[42] A. R. Adamantidis and L. de Lecea, “Sleep and the Hypothalamus,” Science 382, no. 6669 (2023): 405–412.

[43] J. Thompson, M. Bi, A. G. Murchison, et al., “The Importance of Early Immunotherapy in Patients With Faciobrachial Dystonic Seizures,” Brain 141, no. 2 (2018): 348–356.

[44] D. M. Andrade, P. Tai, J. Dalmau, and R. Wennberg, “Tonic Seizures: A Diagnostic Clue of Anti-LGI1 Encephalitis?,” Neurology 76, no. 15 (2011): 1355–1357.

[45] V. Navarro, A. Kas, E. Apartis, et al., “Motor Cortex and Hippocampus Are the Two Main Cortical Targets in LGI1-Antibody Encephalitis,” Brain 139, no. Pt 4 (2016): 1079–1093.

[46] T. R. Li, Y. D. Zhang, Q. Wang, X. Q. Shao, and R. J. Lv, “Recognition of Seizure Semiology and Semiquantitative FDG-PET Analysis of Anti-LGI1 Encephalitis,” CNS Neuroscience & Therapeutics 27, no. 10 (2021): 1173–1181.

[47] M. Upadhya, T. Kirmann, M. A. Wilson, et al., “Peripherally-Derived LGI1-Reactive Monoclonal Antibodies Cause Epileptic Seizures in Vivo,” Brain 147, no. 8 (2024): 2636–2642.

[48] N. W. Seay, R. W. Lehrich, and A. Greenberg, “Diagnosis and Management of Disorders of Body Tonicity-Hyponatremia and Hypernatremia: Core Curriculum 2020,” American Journal of Kidney Diseases 75, no. 2 (2020): 272–286.

[49] A. M. Warren, M. Grossmann, M. Christ-Crain, and N. Russell, “Syndrome of Inappropriate Antidiuresis: From Pathophysiology to Management,” Endocrine Reviews 44, no. 5 (2023): 819–861.

[50] P. D. Acton and K. J. Friston, “Statistical Parametric Mapping in Functional Neuroimaging: Beyond PET and fMRI Activation Studies,” European Journal of Nuclear Medicine 25, no. 7 (1998): 663–667.

[51] H. K. Mak, Z. Zhang, K. K. Yau, L. Zhang, Q. Chan, and L. W. Chu, “Efficacy of Voxel-Based Morphometry With DARTEL and Standard Registration as Imaging Biomarkers in Alzheimer's Disease Patients and Cognitively Normal Older Adults at 3.0 Tesla MR Imaging,” Journal of Alzheimer's Disease 23, no. 4 (2011): 655–664.

[52] T. Zhang, B. Nie, H. Liu, and B. Shan, “Alzheimer's Disease Neuroimaging I. Unified Spatial Normalization Method of Brain PET Images Using Adaptive Probabilistic Brain Atlas,” European Journal of Nuclear Medicine and Molecular Imaging 49, no. 9 (2022): 3073–3085.

[53] B. Nie, S. Liang, X. Jiang, et al., “An Automatic Method for Generating an Unbiased Intensity Normalizing Factor in Positron Emission Tomography Image Analysis After Stroke,” Neuroscience Bulletin 34, no. 5 (2018): 833–841.

[54] P. G. Spetsieris and D. Eidelberg, “Scaled Subprofile Modeling of Resting state Imaging Data in Parkinson's Disease: Methodological Issues,” Neuroimage 54, no. 4 (2011): 2899–2914.

[55] Y. Bai, M. Yun, B. Nie, et al., “Neurometabolism and Ventricular Dyssynchrony in Patients with Heart Failure and Reduced Ejection Fraction,” Journal of the American College of Cardiology 80, no. 20 (2022): 1884–1896.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.